Literature DB >> 11792779

Pathologic fracture in osteosarcoma : prognostic importance and treatment implications.

Sean P Scully1, Michelle A Ghert, David Zurakowski, Roby C Thompson, Mark C Gebhardt.   

Abstract

BACKGROUND: The presence of a pathologic fracture in an osteosarcoma has been considered a poor prognostic factor and an indication for immediate amputation. The purpose of the present study was to determine, in the current era of neoadjuvant chemotherapy, whether a pathologic fracture in an osteosarcoma has prognostic importance and whether limb salvage can be safely performed in such patients without compromising clinical outcome.
METHODS: In a cooperative effort of the Musculoskeletal Tumor Society, members from eight institutions provided retrospective data on fifty-two patients with osteosarcoma who had a pathologic fracture and on fifty-five patients with osteosarcoma who had not had a pathologic fracture and had been followed for at least two years or until disease recurrence, metastasis, or death. The two groups were matched for patient age and tumor location. Outcomes examined were survival and local recurrence. A subgroup analysis was performed to assess differences in outcome within the group with the pathologic fracture.
RESULTS: The five-year estimated survival rates were 55% for the group with a pathologic fracture and 77% for the group without a fracture (p = 0.02). The rate of survival without a local recurrence at five years was 75% for the group with a fracture and 96% for the group without a fracture (p = 0.007). In the group with a fracture, seven (23%) of the thirty patients managed with limb salvage and four (18%) of the twenty-two managed with an amputation had a local recurrence (p = 0.75). Eleven (37%) of the thirty patients with a fracture who were managed with limb salvage and ten (45%) of the twenty-two patients with a fracture who were managed with an amputation died of the disease (p = 0.50). Five patients underwent open reduction and internal fixation followed by limb-salvage surgery. Two of them had a local recurrence and died at an average of eight months postoperatively. The remaining three patients were alive at an average of 6.1 years postoperatively. Local disease control and the survival of these patients were not significantly different from those for the thirty-three patients who were treated with nonoperative immobilization of the fracture followed by limb-salvage surgery.
CONCLUSIONS: Patients with osteosarcoma who present with a pathologic fracture or sustain one during preoperative chemotherapy have an increased risk of local recurrence and a decreased rate of survival compared with patients who have not sustained a pathologic fracture. The performance of a limb-salvage procedure in carefully selected patients with a pathologic fracture does not significantly increase the risk of local recurrence or death. Factors predictive of improved outcome, such as the response to chemotherapy and union of the fracture, should be taken into account when limb salvage is being considered.

Entities:  

Mesh:

Year:  2002        PMID: 11792779

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  36 in total

Review 1.  State-of-the-art approach for bone sarcomas.

Authors:  Andreas F Mavrogenis; Andrea Angelini; Christos Vottis; Emanuela Palmerini; Eugenio Rimondi; Giuseppe Rossi; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-05-03

2.  Pathologic fracture in childhood and adolescent osteosarcoma: A single-institution experience.

Authors:  Lindsay Haynes; Sue C Kaste; Kirsten K Ness; Jianrong Wu; Lucia Ortega-Laureano; Michael Bishop; Michael Neel; Bhaskar Rao; Israel Fernandez-Pineda
Journal:  Pediatr Blood Cancer       Date:  2016-11-05       Impact factor: 3.167

3.  Two case-reports of the limb salvage treatment of osteosarcoma consolidated with obvious pathological fractures.

Authors:  Q Cui; D F Li; C Liu; J Guo; S B Liu; Y S Liu; J M Zhai; Yanjun Zeng
Journal:  Pathol Oncol Res       Date:  2011-01-09       Impact factor: 3.201

4.  The impact of pathological fractures on therapy outcome in patients with primary malignant bone tumours.

Authors:  Babak Moradi; Anita Zahlten-Hinguranage; Burkhard Lehner; Felix Zeifang
Journal:  Int Orthop       Date:  2009-12-13       Impact factor: 3.075

5.  Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma.

Authors:  Eric R Molina; Letitia K Chim; Maria C Salazar; Shail M Mehta; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Tejus Satish; Sana Mohiuddin; David McCall; Ana Maria Zaske; Branko Cuglievan; Alexander J Lazar; David W Scott; Jane K Grande-Allen; Joseph A Ludwig; Antonios G Mikos
Journal:  Acta Biomater       Date:  2019-09-19       Impact factor: 8.947

6.  Telangiectatic osteosarcoma: a review of 87 cases.

Authors:  Andrea Angelini; Andreas F Mavrogenis; Giulia Trovarelli; Stefano Ferrari; Piero Picci; Pietro Ruggieri
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-28       Impact factor: 4.553

7.  Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM-PLGA microspheres for bone cancer treatment.

Authors:  Zi-Jie Rong; Lian-Jun Yang; Bao-Ta Cai; Li-Xin Zhu; Yan-Lin Cao; Guo-Feng Wu; Zan-Jie Zhang
Journal:  J Mater Sci Mater Med       Date:  2016-03-14       Impact factor: 3.896

Review 8.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

9.  Complications and risk factors for failure of rotationplasty: review of 25 patients.

Authors:  Chigusa Sawamura; Francis J Hornicek; Mark C Gebhardt
Journal:  Clin Orthop Relat Res       Date:  2008-04-11       Impact factor: 4.176

Review 10.  Amputation Versus Limb-Salvage Surgery in Patients with Osteosarcoma: A Meta-analysis.

Authors:  Gang Han; Wen-Zhi Bi; Meng Xu; Jin-Peng Jia; Yan Wang
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.